Amarnath Natarajan

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/32107/publications.pdf

Version: 2024-02-01

		186265	214800
93	2,723	28	47
papers	citations	h-index	g-index

102	102	102	4414
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 122-139.	4.1	190
2	Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications, 2017, 53, 7577-7580.	4.1	167
3	Novel Arylsulfoanilideâ^'Oxindole Hybrid as an Anticancer Agent That Inhibits Translation Initiation. Journal of Medicinal Chemistry, 2004, 47, 4979-4982.	6.4	152
4	Impact of structurally modifying hyaluronic acid on CD44 interaction. Journal of Materials Chemistry B, 2017, 5, 8183-8192.	5.8	125
5	Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy. Journal of Medicinal Chemistry, 2016, 59, 8667-8684.	6.4	121
6	Selective degradation of CDK6 by a palbociclib based PROTAC. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 1375-1379.	2.2	95
7	3,3-Diaryl-1,3-dihydroindol-2-ones as Antiproliferatives Mediated by Translation Initiation Inhibition. Journal of Medicinal Chemistry, 2004, 47, 1882-1885.	6.4	90
8	Isatin Derived Spirocyclic Analogues with Î±-Methylene-Î³-butyrolactone as Anticancer Agents: A Structureâ€“Activity Relationship Study. Journal of Medicinal Chemistry, 2016, 59, 5121-5127.	6.4	86
9	Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biology and Therapy, 2011, 11, 263-276.	3.4	69
10	RAC1 GTPase promotes the survival of breast cancer cells in response to hyper-fractionated radiation treatment. Oncogene, 2016, 35, 6319-6329.	5.9	63
11	Synthesis and biological evaluation of thiazolidine-2,4-dione and 2,4-thione derivatives as inhibitors of translation initiation. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 5401-5405.	2.2	54
12	Small Molecule Adenosine 5â€²-Monophosphate Activated Protein Kinase (AMPK) Modulators and Human Diseases. Journal of Medicinal Chemistry, 2015, 58, 2-29.	6.4	51
13	Perturbing pro-survival proteins using quinoxaline derivatives: A structureâ€“activity relationship study. Bioorganic and Medicinal Chemistry, 2012, 20, 2227-2234.	3.0	50
14	Micellar formulation of indocyanine green for phototherapy of melanoma. Journal of Controlled Release, 2015, 220, 130-140.	9.9	49
15	Dual-fluorophore quantitative high-throughput screen for inhibitors of BRCTâ€“phosphoprotein interaction. Analytical Biochemistry, 2008, 375, 60-70.	2.4	47
16	Mutant Cbl proteins as oncogenic drivers in myeloproliferative disorders. Oncotarget, 2011, 2, 245-250.	1.8	43
17	Human Apurinic/Apyrimidinic Endonuclease (APE1) Is Acetylated at DNA Damage Sites in Chromatin, and Acetylation Modulates Its DNA Repair Activity. Molecular and Cellular Biology, 2017, 37, .	2.3	42
18	Synthetic Studies toward Aryl-(4-aryl-4H-[1,2,4]triazole-3-yl)-amine from 1,3-Diarylthiourea as Urea Mimetics. Journal of Organic Chemistry, 2005, 70, 6362-6368.	3.2	41

#	Article	IF	Citations
19	Structureâ€“activity requirements for the antiproliferative effect of troglitazone derivatives mediated by depletion of intracellular calcium. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2547-2550.	2.2	40
20	Inhibition of BRCT(BRCA1)-phosphoprotein interaction enhances the cytotoxic effect of olaparib in breast cancer cells: a proof of concept study for synthetic lethal therapeutic option. Breast Cancer Research and Treatment, 2012, 134, 511-517.	2.5	37
21	Poly-l-proline Type II Peptide Mimics Based on the 3-Azabicyclo[3.1.0]hexane System. Journal of Organic Chemistry, 2001, 66, 455-460.	3.2	33
22	Microwave-assisted cleavage of phosphate, phosphonate and phosphoramide esters. Tetrahedron Letters, 2006, 47, 6281-6284.	1.4	33
23	2,3-Substituted quinoxalin-6-amine analogs as antiproliferatives: A structureâ€“activity relationship study. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 1929-1932.	2.2	33
24	High-throughput fluorescence polarization assay to identify small molecule inhibitors of BRCT domains of breast cancer gene 1. Analytical Biochemistry, 2006, 352, 135-141.	2.4	32
25	Total synthesis of ovalifoliolatin B, acerogenins A and C. Tetrahedron Letters, 2008, 49, 2103-2105.	1.4	32
26	Face selective reduction of the exocyclic double bond in isatin derived spirocyclic lactones. Organic and Biomolecular Chemistry, 2013, 11, 244-247.	2.8	32
27	A Kinase Inhibitor Screen Reveals Protein Kinase C-dependent Endocytic Recycling of ErbB2 in Breast Cancer Cells. Journal of Biological Chemistry, 2014, 289, 30443-30458.	3.4	31
28	Thermodynamics of Phosphopeptide Tethering to BRCT:Â The Structural Minima for Inhibitor Design. Journal of the American Chemical Society, 2007, 129, 10658-10659.	13.7	30
29	Aminopyrazole based CDK9 PROTAC sensitizes pancreatic cancer cells to venetoclax. Bioorganic and Medicinal Chemistry Letters, 2021, 43, 128061.	2.2	30
30	Synthesis and evaluation of macrocyclic diarylether heptanoid natural products and their analogs. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 245-248.	2.2	29
31	Catalytically inactive Dnmt3b rescues mouse embryonic development by accessory and repressive functions. Nature Communications, 2019, 10, 4374.	12.8	28
32	PIK3C3 Inhibition Promotes Sensitivity to Colon Cancer Therapy by Inhibiting Cancer Stem Cells. Cancers, 2021, 13, 2168.	3.7	28
33	Explorations of Substituted Urea Functionality for the Discovery of New Activators of the Heme-Regulated Inhibitor Kinase. Journal of Medicinal Chemistry, 2013, 56, 9457-9470.	6.4	27
34	Targeting the NF-Î¹B and mTOR Pathways with a Quinoxaline Urea Analog That Inhibits IKKÎ² for Pancreas Cancer Therapy. Clinical Cancer Research, 2013, 19, 2025-2035.	7.0	27
35	Novel Treatment for Mantle Cell Lymphoma Including Therapy-Resistant Tumor by NF-Î¹B and mTOR Dual-Targeting Approach. Molecular Cancer Therapeutics, 2013, 12, 2006-2017.	4.1	27
36	Computational and experimental studies of the interaction between phospho-peptides and the C-terminal domain of BRCA1. Journal of Computer-Aided Molecular Design, 2011, 25, 1071-1084.	2.9	25

#	Article	IF	Citations
37	Proteinâ€“protein interactions as therapeutic targets in neuropsychopharmacology. Neuropsychopharmacology, 2009, 34, 247-248.	5.4	23
38	Exploiting the P-1 Pocket of BRCT Domains Toward a Structure Guided Inhibitor Design. ACS Medicinal Chemistry Letters, 2011, 2, 764-767.	2.8	23
39	The human AP-endonuclease 1 (APE1) is a DNA G-quadruplex structure binding protein and regulatesKRASexpression in pancreatic ductal adenocarcinoma cells. Nucleic Acids Research, 2022, 50, 3394-3412.	14.5	23
40	Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget, 2018, 9, 5216-5232.	1.8	22
41	CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology, 2019, 96, 419-429.	2.3	21
42	Characterization of Promiscuous Binding of Phosphor Ligands to Breast-Cancer-Gene 1 (BRCA1) C-Terminal (BRCT): Molecular Dynamics, Free Energy, Entropy and Inhibitor Design. PLoS Computational Biology, 2016, 12, e1005057.	3.2	21
43	Discovery and characterization of small molecule Rac1 inhibitors. Oncotarget, 2017, 8, 34586-34600.	1.8	21
44	Identification of the DNA-Binding Domains of Human Replication Protein A That Recognize G-Quadruplex DNA. Journal of Nucleic Acids, 2011, 2011, 1-14.	1.2	20
45	Structureâ€“Activity Relationship Studies with Tetrahydroquinoline Analogs as EPAC Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 1183-1187.	2.8	19
46	Recent Advances in EPAC-Targeted Therapies: A Biophysical Perspective. Cells, 2019, 8, 1462.	4.1	18
47	Structureâ€“Activity Relationship Studies To Probe the Phosphoprotein Binding Site on the Carboxy Terminal Domains of the Breast Cancer Susceptibility Gene 1. Journal of Medicinal Chemistry, 2011, 54, 4264-4268.	6.4	17
48	The paradox of conformational constraint in the design of Cbl(TKB)-binding peptides. Scientific Reports, 2013, 3, 1639.	3.3	17
49	Development of 1-((1,4-trans)-4-Aryloxycyclohexyl)-3-arylurea Activators of Heme-Regulated Inhibitor as Selective Activators of the Eukaryotic Initiation Factor 2 Alpha (eIF2Î±) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response. Journal of Medicinal Chemistry, 2017, 60, 5392-5406.	6.4	17
50	A mitotic CDK5-PP4 phospho-signaling cascade primes 53BP1 for DNA repair in G1. Nature Communications, 2019, 10, 4252.	12.8	17
51	Inhibitors, PROTACs and Molecular Glues as Diverse Therapeutic Modalities to Target Cyclin-Dependent Kinase. Cancers, 2021, 13, 5506.	3.7	17
52	Synthesis of aminopyrazole analogs and their evaluation as CDK inhibitors for cancer therapy. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3736-3740.	2.2	16
53	Structural characterization of BRCTâ€“tetrapeptide binding interactions. Biochemical and Biophysical Research Communications, 2010, 393, 207-210.	2.1	15
54	High-throughput fluorescence polarization assay to identify inhibitors of Cbl(TKB)â€“protein tyrosine kinase interactions. Analytical Biochemistry, 2011, 411, 254-260.	2.4	15

#	Article	IF	Citations
55	Ferulic acid dimer as a non-opioid therapeutic for acute pain. Journal of Pain Research, 2018, Volume 11, 1075-1085.	2.0	15
56	Synthesis of fluorescein labeled 7-methylguanosinemonophosphate. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 2657-2660.	2.2	14
57	Pharmacokinetics, protein binding and metabolism of a quinoxaline urea analog as an NFâ€Î°B inhibitor in mice and rats by LCâ€MS/MS. Biomedical Chromatography, 2013, 27, 900-909.	1.7	14
58	Optimization of variables for screening solid-supported metal complexes as oxidation catalysts. Tetrahedron Letters, 2000, 41, 5783-5787.	1.4	13
59	Recent Advances in Cancer Drug Development: Targeting Induced Myeloid Cell Leukemia-1 (Mcl-1) Differentiation Protein. Current Medicinal Chemistry, 2018, 24, 4488-4514.	2.4	13
60	Selective killing of homologous recombination-deficient cancer cell lines by inhibitors of the RPA:RAD52 protein-protein interaction. PLoS ONE, 2021, 16, e0248941.	2.5	13
61	Synthesis and screening of 3-substituted thioxanthen-9-one-10,10-dioxides. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 5940-5943.	2.2	12
62	High-throughput compatible fluorescence resonance energy transfer-based assay to identify small molecule inhibitors of AMSH deubiquitinase activity. Analytical Biochemistry, 2013, 440, 71-77.	2.4	12
63	Oncogenic Signaling by Leukemia-Associated Mutant Cbl Proteins. Biochemistry and Analytical Biochemistry: Current Research, 2013, 02, .	0.4	12
64	Peptide Truncation Leads to a Twist and an Unusual Increase in Affinity for Casitas B-Lineage Lymphoma Tyrosine Kinase Binding Domain. Journal of Medicinal Chemistry, 2012, 55, 3583-3587.	6.4	11
65	Pulse design for broadband correlation NMR spectroscopy by multi-rotating frames. Journal of Biomolecular NMR, 2013, 55, 291-302.	2.8	11
66	Synthesis of Conformationally Constrained Lysine Analogues. Journal of Organic Chemistry, 2006, 71, 5004-5007.	3.2	10
67	Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. ACS Chemical Biology, 2018, 13, 1148-1152.	3.4	10
68	Symbiotic prodrugs (SymProDs) dual targeting of NFkappaB and CDK. Chemical Biology and Drug Design, 2020, 96, 773-784.	3.2	10
69	Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKÎ² phosphorylation for pancreatic cancer therapy. European Journal of Medicinal Chemistry, 2021, 222, 113579.	5.5	9
70	Molecular diversity approach to the synthesis of peptide-derived ruthenium complexes and their evaluation as oxidation catalysts. Tetrahedron Letters, 2000, 41, 5789-5793.	1.4	8
71	Poly-l-proline type II peptide mimics as probes of the active site occupancy requirements of cGMP-dependent protein kinase. Chemical Biology and Drug Design, 2005, 66, 151-159.	1.1	8
72	A simple fluorescent assay for the discovery of protein-protein interaction inhibitors. Analytical Biochemistry, 2019, 569, 46-52.	2.4	8

#	Article	IF	Citations
73	EHD1 and RUSC2 Control Basal Epidermal Growth Factor Receptor Cell Surface Expression and Recycling. Molecular and Cellular Biology, 2020, 40, .	2.3	8
74	Irreversible binding of an anticancer compound (BI-94) to plasma proteins. Xenobiotica, 2015, 45, 858-873.	1.1	7
75	Protein kinase RNA-activated controls mitotic progression and determines paclitaxel chemosensitivity through B-cell lymphoma 2 in ovarian cancer. Oncogene, 2021, 40, 6772-6785.	5.9	7
76	Small molecule binding to inhibitor of nuclear factor kappa-B kinase subunit beta in an ATP non-competitive manner. Chemical Communications, 2021, 57, 4678-4681.	4.1	6
77	Stapling proteins in the RELA complex inhibits TNFÎ±-induced nuclear translocation of RELA. RSC Chemical Biology, 2022, 3, 32-36.	4.1	6
78	Systemic Administration of a Brain Permeable Cdk5 Inhibitor Alters Neurobehavior. Frontiers in Pharmacology, 2022, 13, .	3.5	6
79	Synthesis of unnatural amino acid derivatives via palladium-catalyzed 1,4-addition of boronic acids. Tetrahedron Letters, 2010, 51, 2655-2656.	1.4	5
80	A quinoxaline urea analog uncouples inflammatory and pro-survival functions of IKKÎ². Immunology Letters, 2015, 168, 319-324.	2.5	5
81	Mouse Pancreatic Tumor Model Independent of Tumor Suppressor Gene Inactivation. Pancreas, 2018, 47, e27-e29.	1.1	5
82	Spirocyclic dimer SpiD7 activates the unfolded protein response to selectively inhibit growth and induce apoptosis of cancer cells. Journal of Biological Chemistry, 2022, 298, 101890.	3.4	5
83	Dimers of isatin derived Î±-methylene-Î³-butyrolactone as potent anti-cancer agents. Bioorganic and Medicinal Chemistry Letters, 2022, 65, 128713.	2.2	5
84	Fbxo7 promotes Cdk6 activity to inhibit PFKP and glycolysis in T cells. Journal of Cell Biology, 2022, 221, .	5.2	5
85	Novel Treatment for Therapy-Resistant Mantle Cell Lymphoma Targeting NF-ÎºB and mTOR Signaling Pathways in Vitro and in Vivo. Blood, 2012, 120, 63-63.	1.4	4
86	Selective CDK9 degradation using a proteolysis-targeting chimera (PROTAC) strategy. Future Medicinal Chemistry, 2022, 14, 131-134.	2.3	4
87	Small molecule induced polymerization of BCL6 facilitates SIAH1 mediated degradation. Signal Transduction and Targeted Therapy, 2021, 6, 142.	17.1	3
88	Small-molecule IKKÎ² activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, e2115071119.	7.1	3
89	Beyond the frog: The evolution of homology models of human IKKÎ². Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6081-6084.	2.2	1
90	Synthetic Studies Toward Aryl-(4-aryl-4H-[1,2,4]triazole-3-yl)-amine from 1,3-Diarylthiourea as Urea Mimetics.. ChemInform, 2005, 36, no.	0.0	0

#	Article	IF	Citations
91	Discovery, synthesis and biological evaluation of substituted urea: new activators of heme regulated inhibitor. FASEB Journal, 2013, 27, lb585.	0.5	0
92	Cinnamic Acid Derivatives as Novel Antinociceptives for Acute Pain. FASEB Journal, 2018, 32, 684.9.	0.5	0
93	A Novel Spirocyclic Dimer (36-286) Targeting the NF-Kappa B Pathway Displays Potent Anti-Tumor Properties in Chronic Lymphocytic Leukemia. Blood, 2021, 138, 1186-1186.	1.4	0